People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.

Proper nutrition is critical to long-term weight loss success. Knowing what to eat while taking Wegovy® (semaglutide) can help you feel your best. Wegovy mimics a naturally occurring hormone ...

Wegovy is a semaglutide drug approved as a treatment for weight management as well as serious cardiovascular issues. It works by suppressing appetite and reducing blood sugar levels. It is ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

The drug, which contains the active ingredient semaglutide, works by reducing ... presented by the manufacturer Novo Nordisk, shows Wegovy can protect against heart disease in the earliest stages ...

None had diabetes, The Associated Press reported. Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an ...

Weight loss injections may have an anti-cancer effect "beyond weight loss", a new study suggests. Obesity is linked to 13 different cancers. Scientists have long known that losing weight can slash ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that Zepbound (tirzepatide) demonstrated a significantly greater weight reduction compared to Wegovy (semaglutide) in all comparisons conducted during ...

Participants received weekly injections of either Zepbound (tirzepatide) or Wegovy (semaglutide). After 72 weeks, people taking Zepbound lost an average of 50 pounds. Those on Wegovy lost about 33 ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings. kAm!6@A=6 E2<:?8 t=: {:==J’D @36D:EJ 5CF8[ k2 ...